Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued on Thursday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

RVNC has been the subject of several other research reports. HC Wainwright reiterated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays reduced their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Finally, Mizuho reduced their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Thursday. Revance Therapeutics has a one year low of $2.30 and a one year high of $7.56. The firm has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The firm has a 50-day simple moving average of $3.39 and a 200-day simple moving average of $4.59.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. On average, research analysts predict that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Alpine Associates Management Inc. purchased a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $21,605,000. LMR Partners LLP purchased a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $11,648,000. Oddo BHF Asset Management Sas purchased a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $3,763,000. Wellington Management Group LLP purchased a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $2,315,000. Finally, Exome Asset Management LLC purchased a new stake in shares of Revance Therapeutics in the 3rd quarter valued at $1,804,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.